NCT00305656View on ClinicalTrials.gov

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2012

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

cediranib maleate

Given orally

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00305656 - AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter